Chemoproteomics-Enabled De Novo Discovery of a Metallothionein Degrader Enables Probing Their Role in Cancer Cells

12 August 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Proteolysis targeting chimeras (PROTACs) represent powerful tools to modulate the activity of classically “undruggable” proteins, but their application has been limited to known ligands and a few select protein classes. Herein, we present our chemoproteomic strategy for de novo discovery of PROTAC degraders. Using comparative PROTAC versus ligand global proteomics analyses, we rapidly identify proteins selectively downregulated by “untargeted” PROTAC probes containing an E3 ligase recruiter and various cysteine-reactive protein-of-interest (POI) ligands. In this manuscript, we showcase our approach by identifying a first-in-class acrylamide- and VHL-based PROTAC for metallothionein 2A (MT2A) – a small, cysteine-rich, metal-binding protein implicated in heavy metal detoxification, zinc homeostasis, and cellular metastasis. Notably, isoform-specific MT overexpression has been shown to augment cellular migration and invasion across several cancer cell lines, though precise mechanisms are unknown due to insufficient tools to study MTs. We show that optimized PROTAC AA-BR-157 covalently binds conserved C44, degrades overexpressed MT2A with nanomolar potency, and reduces migration and invasion of triple negative breast cancer MDA-MB-231 cells. We further demonstrate a time-dependent increase in intracellular zinc levels following MT2A degradation as well as downregulation of protein diaphanous homolog 3 (DIAPH3), a positive regulator of actin and cell motility. Super-resolution imaging of MDA-MB-231 cells shows that downregulation of MT2A and DIAPH3 inhibits cell polarization and thereby migration, suggesting that MT2A regulates motility via DIAPH3-dependent cytoskeletal remodeling. In summary, our strategy enables the discovery of PROTACs for novel disease-related targets and lays the groundwork for expansion of the druggable proteome.

Keywords

proteolysis targeting chimera
chemical proteomics
metallothioneins
cancer

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
Experimental procedures, supporting figures, chemical synthesis, and spectra
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.